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ZUSAMMENFASSUNG 
 
Myeloproliferative Neoplasien (MPN) sind klonale hämatologische Erkrankungen, welche zu 
den myeloischen Malignomen gehören. Laut der WHO Klassifizierung von 2008, gehören 
Polycythämia vera (PV), Essentielle Thrombozythämie (ET), Primäre Myelofibrose (PMF), 
Chronische myeloische Leukämie (CML), Chronische Neutrophilenleukämie (CNL), 
Chronische Eosinophilenleukämie (CEL), Systemische Mastozytose (SM) und 
unklassifizierbare Myeloproliferative Neoplasien zu den MPN. Das Hauptmerkmal von MPN 
ist die übermäßige Bildung von terminal differenzierten Blutzellen, die zu der myeloischen 
Reihe gehören. Die individuellen klinischen Merkmale der drei klassischen                      
BCR-ABL1-negativen MPN sind Erythrozytose in PV, Thrombozythämie in ET und 
Fibrosierung des Knochenmarkgewebes in PMF. Eine Transformation zur akuten Leukämie 
ist, neben Thrombose, die größte Komplikation von MPN aufgrund von einer schlechten 
Prognose und einer voraussichtlichen Lebensdauer von 5 Monaten. Diese Studie konzentriert 
sich auf den drei klassischen BCR-ABL1-negativen MPN, PV, ET und PMF und deren 
Transformation zu AML.  
In 29 Patienten unserer Kohorte wurden Deletionen und uniparentale Disomien (UPD) von 
Chromosom 7q gefunden und in einer der Deletionen befand sich nur CUX1. Es wurde 
berichtet, dass Deletionen von Chromosom 7q mit der Transformation assoziiert sind, 
deswegen wurde eine Sequenzanalyse von CUX1 und SH2B2, das 1kb von CUX1 entfernt 
liegt, in Patienten, die akute Leukämie entwickelt haben, durchgeführt.  
Als Methode zur Aufklärung der Konsequenzen von CUX1 und SH2B2 Deletionen wurden 
shRNAs,  die gegen die spezifischen Gene gerichtet waren, in der Baf3/EpoR Zelllinie 
getestet. Die Wachstumskinetik der transduzierten Zelllinien hat keinen Effekt von den 
shRNAs gezeigt.  
TP53 wurde in 24 Patienten, die eine Krankheitsprogression zu sMF oder AML erfahren 
haben, sequenziert. Es wurde berichtet, dass auch dieses Gen mit der Tranformation von MPN 
Patienten assoziiert ist. In unserer Kohorte wurden 5 somatische Mutationen (21%) gefunden.  
Diese Resultate liefern Beweise zu der Komplexität von MPN. Die Identifikation dieser neuen 
genetischen Veränderungen in MPN Patienten könnte Auswirkungen auf bessere 
Möglichkeiten der Diagnose und Therapie haben.  
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ABSTRACT 
 
Myeloproliferative neoplasms (MPN) are clonal hematologic diseases that belong to the 
myeloid malignancies. According to the 2008 WHO classification, diseases that are 
considered MPN include polycythemia vera (PV), essential thrombocythemia (ET), primary 
myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia 
(CNL), chronic eosinophilic leukemia (CEL), hypereosinophilic syndrome (HES), mast cell 
disease, and unclassifiable myeloproliferative neoplasms. The main phenotypic feature of 
MPN is the excessive production of terminally differentiated blood cells, belonging to the 
myeloid lineage. The individual clinical features of the classical BCR-ABL1-negative MPN 
are erythrocytosis in PV, thrombocythemia in ET, and replacement of the bone marrow by 
fibrotic tissue in PMF. Transformation into post-MPN AML is, besides thrombosis, the main 
complication of MPN, because of the poor prognosis and a mean survival of 5 months. This 
study focuses on the three classical BCR-ABL1-negative MPN, PV, ET, and PMF, and their 
transformation to leukemia. 
Deletions and uniparental disomies (UPDs) of chromosome 7q were found in 29 patients from 
our cohort, and one of them carried a single gene deletion which contained CUX1. Deletions 
of chromosome 7q were reported to be associated with transformation, and because of this, 
sequence analysis of CUX1 and SH2B2, which is located 1kb away from CUX1, was 
performed in patients that developed post-MPN AML. 
As an approach to elucidate the consequences of CUX1 and SH2B2 deletion, RNA short 
hairpins targeting the specific genes were tested in the Baf3/EpoR cell line. Transduced cell 
lines did not reveal an effect of the hairpins in growth kinetics.  
TP53 was sequenced in 24 patients that experienced disease progression either to sMF or 
post-MPN AML. This gene was also reported to be associated with transformation of MPN 
patients and in our cohort 5 somatic mutations (21%) were found. 
These results provide evidence of the complexity of MPN. The identification of these new 
genetic alterations in MPN patients could have implications in better diagnosis and treatment 
possibilities.  
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1 INTRODUCTION 
1.1 Myeloproliferative neoplasms  
Myeloproliferative neoplasms (MPN), according to the 2008 classification of the World 
Health Organisation (WHO), comprise nine clonal hematologic diseases. They belong to the 
myeloid malignancies, which include also acute myeloid leukemia (AML), myelodysplastic 
syndromes (MDS), MDS/MPN, and 
MPN eosinophilia (MPN-eos) (figure 
1). MPN share the main phenotypic 
feature of excessive production of 
terminally differentiated blood cells, 
such as those of the granulocytic 
(neutrophil, eosinophil, basophil), 
monocytic/macrophage, erythroid, 
megakaryocytic and mast cell 
lineages. The three classical BCR-
ABL1-negative MPN are 
polycythemia vera (PV), essential 
thrombocythemia (ET), and primary myelofibrosis (PMF). Other diseases that are considered 
MPN under the 2008 WHO classification include chronic myelogenous leukemia (CML), 
chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), 
hypereosinophilic syndrome (HES), mast cell disease, and unclassifiable myeloproliferative 
neoplasms (figure 1).2 
In 1951 William Dameshek 
described in the Blood journal 
editorial entitled “Some speculations 
on the myeloproliferative 
syndromes” the clinical and 
pathologic similarities and the 
common origin of CML, PV, ET, 
and PMF.3 Later, analyses of         
X-chromosome inactivation patterns 
Figure 1 The 2008 WHO classification for myeloid neoplasms
1
 
Figure 2 Clonal origin of MPN (kindly provided by Dr. Robert Kralovics) 
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in female patients showed that MPN are clonal disorders arising from a transformation of a 
single hematopoietic stem cell (figure 2).4 Adamson et al. showed that peripheral blood cells 
from a PV patient expressed only one isoform of the polymorphic X-linked G6PD gene, 
proving that these cells originated from one clone5 and other studies confirmed this finding 
also for ET and PMF patients.6-7  X-chromosome-based clonality assays have the advantage 
that they can confirm the clonal origin of pathologic cells in disorders in which the reasons for 
clonality are unknown, but this information is restricted only to women.4  
MPN display different phenotypes. For example, chronic myeloid leukemia (CML) is 
characterized by the BCR-ABL1 fusion gene resulting from a reciprocal translocation between 
chromosomes 9 and 22 (t(9;22)(q34;q11), Philadelphia chromosome).8-11 The individual 
clinical features of the classical Philadelphia chromosome-negative MPN are increased 
erythrocyte cell counts 
(erythrocytosis) in PV, elevated 
platelet levels (thrombocythemia) 
in ET, and replacement of the bone 
marrow by fibrotic tissue in PMF 
(figure 3). Although each of the 
MPN is recognized as a distinct 
clinicopathological entity, they share common features, such as hyperproliferation of 
terminally differentiated blood cells, bone marrow hypercellularity, tendency to thrombosis 
and hemorrhage, and a risk of secondary leukemic transformation.12-13 The estimated annual 
incidence of PV, ET, and PMF is five out of 100,000.14-15 
Besides the sporadic MPN form, there are also cases of familial MPN, which is an autosomal 
dominantly inherited disease with incomplete penetrance. It is also characterized by the fact 
that the three classical Philadelphia chromosome-negative MPN can be variably presented in 
a single family, and that its clinical and molecular features cannot be distinguished from 
sporadic MPN.16-17 Most probably an unknown germline mutation predisposes carriers to 
acquire other mutations and develop MPN.18 
 
Figure 3 Laboratory features of PV, ET, and PMF
12
 
11 
 
1.2 Transformation 
The disease course of MPN is generally chronic, but some patients progress into post-PV or 
post-ET secondary myelofibrosis (sMF), into an “accelerated phase” (AP) or transform into 
acute leukemia. The rate of progression to sMF is 10-20% after 15-20 years.19-20 
Transformation into post-MPN AML is, besides thrombosis, the main complication of MPN, 
because of the poor prognosis and a mean survival of 5 months.21 The yearly risk for 
transformation is 0.38% for PV, 0.37% for ET, and 1.09% for PMF.22  
Disease progression is associated with aberrations of chromosomes 1q and 9p, and 
transformation with gains of 1q, and 3q, deletions of 7q, 5q, 6p, and 7p, and uniparental 
disomies of 19q, and 22q (figure 4). This was shown by comparison of the distribution of 
chromosomal abnormalities between samples in chronic phase, sMF/AP, and post-MPN 
AML. Commonly affected regions were mapped to target genes on chromosomes                 
3p (FOXP1), 
4q (TET2),   
7p (IKZF1),  
7q (CUX1), 
12p (ETV6), 
and 21q 
(RUNX1). It 
was shown that 
patients with sMF/AP had significantly more chromosomal aberrations than patients in the 
chronic phase and less compared to the ones with post-MPN AML. It was also found that 
there is no association of disease duration with the frequency of chromosomal aberrations 
which could theoretically accumulate during the evolution of the malignant clone. On the 
other hand the patients’ age at the time of sample associated with the number of defects.21 One 
of the chromosomal aberrations that are most significantly associated with sMF/AP and post-
MPN AML are gains on chromosome 1q. The common amplified region of 1q contains the 
MDM4 gene, which is an inhibitor of p53 that is also associated with post-MPN AML.21,23 
The CDR of chromosome 7q contained the CUX1 gene (cut-like homeobox 1). This deletion 
is one of the most significantly associated with post-MPN AML.21,24 Knowing the 
modifications leading to MPN disease progression could be important for new therapies 
which could prevent the transformation to post-MPN AML.21 
Figure 4 Association of individual chromosomal aberrations with progression to post-MPN AML
21
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1.3 JAK2 
Originally, it was thought that the elevated production of blood cells in MPN is due to 
hypersensitivity of hematopoietic progenitors to cytokines. It was demonstrated in 1974 by 
Prchal and Axelrad that endogenous erythroid colonies (EEC), which are an indicator of 
abnormal in vitro growth of hematopoietic progenitors, grow without exogenous 
erythropoietin.25 Already early reports were suggesting that JAK-STAT signaling may play a 
role in the pathogenesis of PV, ET, and PMF. One of the arguments in favor of this 
hypothesis was that JAK2-knockout mice didn’t have any erythropoiesis and were embryonic 
lethal.26-27 
Further investigations applying different experimental approaches led to the identification of a 
gain-of-function mutation in the Janus kinase 2 gene (JAK2, 9p24)28-32 that is present in 
almost all patients with PV (90-95%),30 and in 50-60% of patients with ET or PMF.33 
Aberrant signaling caused by mutations in tyrosine kinases is a common characteristic for 
MPN. Some examples for this are the BCR-ABL translocation in CML, FIP1L1-PDGFRA in 
CEL, and PDGFRA/B translocations in chronic myelomonocytic leukemia and MDS/MPN 
overlap diseases often associated with eosinophilia.33 The activating mutation was found by 
four different approaches. One of it was to make a microsatellite mapping to define the region 
of 9p containing the JAK2 gene.28 Another was to use siRNA against JAK2 which impaired 
erythroid-terminal differentiation and blocked EEC formation.30 Other groups sequenced the 
tyrosine kinase genome of MPN patients.29,31 
The JAK2 gene encodes a cytoplasmic tyrosine kinase that is essential in signal transduction 
of hematopoietic cytokines, as for example erythropoietin (Epo), thrombopoietin (Tpo), IL-3, 
granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage CSF (GM-CSF) 
receptors. The JAK family 
of proteins contains four 
kinases, JAK1, JAK2, 
JAK3, and TYK2, which 
have essential, non-
redundant roles in 
cytokine signaling.34 The 
JAK2 kinase is bound to 
cytokine receptors without Figure 5 Role of JAK2 in pathway signaling and erythropoietin binding12 
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intrinsic kinase activity (e.g. the erythropoietin receptor) in the endoplasmic reticulum and is 
required for their cell-surface expression.35 When erythropoietin binds to the extracellular 
domain of the erythropoietin receptor, it provokes a conformational change36-38 and a 
subsequent phosphorylation and activation of JAK2.39 The activated JAK2 kinase then 
phosphorylates the receptor’s cytoplasmic domain and thus, promotes docking of downstream 
effector proteins via recruitment of SH2-domain containing proteins, such as STAT3 and 
STAT5,41-42 and initiates intracellular signaling cascades (figure 5).40-41 STAT proteins get 
phosphorylated in that way by JAK2, dimerize and translocate to the nucleus, where they 
activate the transcription of genes involved in many cellular processes.41-42 The activity of 
JAK2 is regulated by the requirement to bind to specific domains in receptors, suppression of 
activation by the pseudokinase domain, and the requirement for phosphorylation within the 
activation loop.34 
JAK2 has three specific domains – the typical kinase domain (JH1), a pseudokinase domain 
(JH2), and regions of homology (JH3–7) located in the N-terminal half of the protein and 
unique among the JAK family of proteins. The amino terminal domain (JH5-7) which 
contains the FERM domain and a region of receptor homology (box 1 and box 2 domains) is 
needed for association with cytokine 
receptors.34 The acquired guanine-to-
thymidine mutation at position 1849 of 
the JAK2 gene, which was identified in 
MPN patients, causes a phenylalanine for 
valine substitution at codon 617 (JAK2-
V617F).28-31 As the mutation lies within 
the pseudokinase domain of JAK2, it 
disrupts its kinase-regulatory activity and 
causes constitutive activation of the 
kinase in the absence of ligand       
(figure 6).43 Furthermore, it results in 
cytokine-independent activation of the JAK-STAT, PI3K, and RAS-MAPK signaling 
pathways (figure 5),28,30-31,44 involved in erythropoietin-receptor signaling.39,45-47 It has been 
shown that overexpression of JAK2-V617F in cell lines leads to phosphorylation of JAK2 in 
the absence of cytokine stimulation and that these cells exhibit cytokine independence or 
hypersensitivity.28-30 
Figure 6 Structure of JAK2 and JAK2-V617F
34
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Expression of JAK2-V617F in murine hematopoietic cells by a retroviral vector recapitulates 
the clinical features of PV, especially erythrocytosis.48-49 On the other hand, transgenic models 
with more physiologic levels of JAK2-V617F expression resemble ET and PMF.50-52      
JAK2-V617F allele burden in MPN patients has been also measured in some studies. It tends 
to be highest in PV and PMF patients and lower in patients with ET.52-53 Two studies showed 
that in PV patients there is an association between higher JAK2-V617F allele burden and 
leukocytosis.54-55 These observations confirm that there is a causal link between the        
JAK2-V617F mutation and the MPN phenotype and that the pathogenesis of MPN is 
characterized through its heterogeneity.12,18 Some studies also suggest that the effects of the 
mutation can be modified by the individual genetic background. In C57Bl/6 mice, 
transplantation with JAK2-V617F-transduced cells resulted in a PV-like disease,49,56-57 
however, in Balb/C mice, the transplantations resulted not only in erythrocytosis, but also 
leukocytosis, and a development of myelofibrosis.48 
Other mutations in JAK2 have been also identified, lying in the exon 12 region of the gene. A 
combination of missense, insertion, or deletion mutations was found, all located just 5’ of the 
pseudokinase domain.58-59 This finding was supported by cell line experiments, a retroviral 
transplant assay and subsequent studies which were performed on more patients.60-62 In 
contrast to JAK2-V617F, the exon 12 mutations appear only in PV patients.58 
Many of the patients with PV or PMF are homozygous for JAK2-V617F. The mechanism 
leading to homozygosity is not loss of the wild-type allele, but uniparental disomy (UPD), 
resulting from mitotic recombination affecting chromosome 9p, and duplication of this region 
(figure 7). Mitotic 
recombination is due to 
an exchange of 
chromosomal DNA 
between non-sister 
chromatids during 
mitosis. The observed 
breakpoints are spread 
between the JAK2 locus and the centromere,18,28  indicating that there is no single fragile site 
that is susceptible to recombination.12 Acquired UPD is thought to be one of the genetic 
mechanisms involved in tumor suppressor inactivation, because it leads to homozygosity of 
mutated or deleted alleles of tumor suppressors via mitotic recombination.63-66 UPD can be 
Figure 7 Mitotic recombination as the mechanism of 9pLOH
12
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detected by comparing genotypes of tumor and non-tumor-derived DNA samples and 
assessing polymorphic DNA markers such as single nucleotide polymorphisms (SNPs), 
microsatellite markers (simple repeat sequences), insertion-deletion polymorphisms or tandem 
repeats.18 
In 2009 a common haplotype that contains the JAK2 gene and preferentially acquires JAK2 
mutations was identified. Investigations revealed a nonrandom distribution of the somatic 
JAK2-V617F mutation between two parental alleles. Moreover, it was shown that more than 
80% of all JAK2-V617F mutations occur on this specific haplotype, which is referred to as the 
JAK2 GGCC haplotype.67-68 Disease-associated SNPs and haplotypes which are identified by 
genome-wide association studies are thought to influence either the expression of genes or the 
sequence of the proteins they encode. A certain combination of SNPs could make a haplotype 
differentially susceptible to somatic mutagenesis. 67-68 Two alternative hypotheses were made 
to explain this observation. One of it is that JAK2 mutations occur randomly on both 
haplotypes, but the GGCC haplotype has specific properties necessary to propagate MPN 
disease phenotype. Alternatively, the GGCC haplotype is more prone to somatic mutagenesis 
and mutations of the JAK2 gene occur more frequently on this specific haplotype. However, 
the mechanism by which this differential mutability of haplotypes might be reached remains 
to be resolved.67-68 
1.4 Other mutations 
Most MPN patients carry an activating JAK2 or MPL mutation, but some have also SH2B3, 
CBL, TET2, ASXL1, IDH, IKZF1, or EZH2 mutations (figure 8).1 
The main known phenotypic mutations in MPN are JAK2-V617F,28-31 JAK2 exon 12 
mutations (JAK2-ex12),59 and mutations of the thrombopoietin receptor gene MPL such as 
MPL-W515L, MPL-W515K, MPL-S505N, MPL-A506T, and MPL-A519T.69-72  
JAK2-ex12 mutations have been found in about 1% of JAK2-V617F negative PV patients, but 
not in other MPN.58 However, due to the rarity of this mutation it is difficult to predict 
whether other MPN also harbor JAK2-ex12 mutations at lower frequencies.59,61  
Activating gain-of-function mutations in the thrombopoietin receptor gene MPL 
(myeloproliferative leukemia virus, 1p34) were identified in about 10% of patients with 
JAK2-V617F-negative PMF and in 3% of patients with V617F-negative ET, but not in   
16 
 
PV.69-71,73 Expression of MPL-W515L establishes factor independent growth in hematopoietic 
cells while activating STAT, MAPK and PI3K–Akt signaling pathways in a similar fashion to 
JAK2-V617F. JAK2-V617F and MPL-W515L activate similar signaling pathways when 
expressed in vitro, but MPL-W515L expression in vivo results in marked thrombocytosis and 
myelofibrosis.74  
c-CBL (casitas B-lineage lymphoma, 11q23.3) mutations in myeloid malignancies are usually 
associated with 11q UPD.75 In a recent study on MPN patients, the mutations were only found 
in either exon 8 or 9 in 6% of patients with PMF.76 Cbl proteins are multifunctional adaptor 
proteins and E3 ubiquitin ligases which are involved in the trafficking and degradation of 
activated tyrosine kinases.77  
TET2 (TET oncogene family member 2, 4q24) can be found in JAK2-V617F positive and 
negative MPN. The mutational frequencies are around 16% in PV, 5% in ET, and 17% in 
PMF.78-79 Together with ASXL1, TET2 could contribute to the epigenetic regulation of 
hematopoiesis.79-80  
ASXL1 (additional sex combs-like 1, 20q11.1) mutations are seen in around 8% of MPN 
patients. A heterozygous ASXL1 mutation was identified in five MPN patients who were all 
JAK2-V617F negative.81 
IDH1 and IDH2 (isocitrate dehydrogenase, 2q33.3 and 15q26.1) were found in 1,9% of PV, 
0,8% of ET, and 4,2% of PMF patients.82 Functional characterization of IDH mutations 
suggests neoenzymatic activity in converting α-ketoglutarate to the possibly oncogenic         
2-hydroxyglutarate.1 
IKZF1(IKAROS family zinc finger 1, 7p12) mutation frequency is 0,2% in chronic phase PV, 
ET, and PMF patients, but 21% in blast phase patients, which shows that there is a significant 
association of IKZF1 deletions with leukemic transformation.83 IKZF1 encodes a transcription 
factor which has a pleiotropic function in the regulation of hematopoiesis.84 Functional studies 
in mouse models suggest that decreased Ikaros function is oncogenic.84-88 
EZH2 (encodes the catalytic subunit of the polycomb repressive complex 2, 7q36.1) was 
reported to be a target of 7qUPDs,89-90 and suggested to be a tumor suppressor in myeloid 
malignancies.89 
17 
 
 
Figure 8 Mechanisms and pathways targeted by mutations in MPN
91
 
 
Host modifiers, previous and subsequent mutations have also been postulated to play a role in 
MPN pathogenesis.92-94 In accordance with this hypothesis, murine models of JAK2-V617F 
positive MPN show pronounced strain-specific variation in phenotype, including variability in 
the degree of leukocytosis and fibrosis.56 
1.5 Chromosomes 7q and 12q 
CUX1 (cut-like homeobox 1, CUTL1, CDP) is located on chromosome 7q and encodes a 
transcription factor that has a role in cell cycle regulation, cell motility, invasion, and 
hematopoiesis.95-99 An increase in CUX1 expression has been observed during cell cycle 
progression following exit from quiescence100-101, following TGF-β stimulation96, in breast 
tumors and cancer cell lines102, in malignant plasma cells103, and in acute lymphoblastic 
leukemia.104 
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CUX1 is located on 7q22 and contains 33 exons. Resulting from proteolytic processing or 
transcription 
initiation at an 
alternative start site, 
at least three protein 
isoforms can be 
expressed in human 
(p200, p110, p75). In 
mice there were 
additional isoforms 
identified – p75, p80, 
p90, p110, p150 and 
p200 (figure 9).95,97 They have distinct DNA binding and transcriptional properties.95 The 
p200 form of CUX1 has four conserved DNA-binding domains, three Cut repeats and one Cut 
homeodomain (HOX). Originally, CUX1 was shown to function as a transcriptional repressor 
that down-regulates lineage specific genes in precursor cells that later become expressed in 
terminally differentiated cells.95,97,105 The expression and activity of CUX1 are regulated by 
alternative transcription initiation, proteolytic processing, phosphorylation and acetylation.95 
Three knock-out mouse models have been generated for CUX1. In the first model only the 
Cut repeat 1 was lacking and this resulted in mice with wavy hair, curly whiskers from day    
2 to day 19, and impaired lactation in homozygous females that resulted in a high percentage 
(50%) of post-natal lethality in their litters.97,106 In another model the CUX1 protein was 
truncated after the Cut repeat 3 and lacked the Cut homeodomain and the carboxy-terminal 
region. Only few homozygous mice survived to weaning age and these failed to thrive, had a 
reduced stature, gained little weight, had wavy whiskers and lost fur at 2 or 3 weeks of age. 
Homozygous mutant mice had also a reduction in the number of B cells in the bone marrow, 
and the number of T cells was reduced 5-fold in the thymus. On the other hand there was an 
increase in the number of myeloid cells in the bone marrow, spleen and peripheral blood. This 
showed that CUX1 expression is important for homeostasis in the hematopoietic system.107-108 
In the third model exons 22 and 23 (most of the Cut repeat 3 and the entire Cut 
homeodomain) were replaced with LacZ. 99% of homozygous mice died after birth because 
of respiratory failure, and the surviving mice displayed growth retardation and an abnormal 
hair coat.109 
Figure 9 Cux1 isoforms exhibit distinct DNA binding and transcriptional properties
95
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There were also many CUX1 transgenic mouse models generated. In one case, the mice 
developed multiorgan organomegaly, and the higher cell number was due to a higher number 
of proliferating cells. This indicates that Cux1 expression does not interfere with terminal 
differentiation.109-110 Other transgenic mice were designed to compare the different isoforms 
of CUX1. Most of the p75 mice suffered from a MPN-like myeloid leukemia which was 
characterized by splenomegaly, hepatomegaly, and frequent infiltration of leukocytes into 
non-hematopoietic organs. It was impossible to transplant the disease into recipient mice 
which would suggest that expression of the p75 CUX1 transgene did rather take place in a 
committed myeloid progenitor than in the hematopoietic stem cell.99  
Region 7q22 where CUX1 is located, is a region which is frequently deleted in uterine 
leiomyomas,111 acute myeloid leukemia,112 and myelodysplastic syndromes.113 In one study 
there was a patient found which had a 0.88Mb deletion on chromosome 7q which contained 
only the genes CUX1 and SH2B2.114 Recently, a missense mutation in the HOX domain of 
CUX1 was identified through a previous screen of a large cohort of BCR-ABL1-negative MPN 
patients at the time of leukemic transformation. The complexity of 7q rearrangements 
suggests that maybe not a mutation in a single gene, but the alteration of different genetic 
factors could be an important part of the pathogenesis in patients with deletions of 
chromosome 7q.105 
The gene located right after CUX1 on chromosome 7q is SH2B2. The SH2B family has three 
members, SH2B1 (SH2-B), SH2B2 (APS), and SH2B3 (LNK). All of them contain an            
N-terminal dimerization (DD), a central pleckstrin homology (PH), and a C-terminal SH2 
domain (figure 10).115-117 
SH2B2 is an adaptor 
protein that binds via the 
SH2 domain to JAK2, 
and subsequently 
phosphorylates the 
insulin receptor. SH2B2 may regulate by this means energy balance and body weight by 
enhancing JAK2-mediated cytokine signaling.117 It also increases insulin signaling in cultured 
cells,119 but surprisingly a deletion of SH2B2 results in enhanced insulin sensitivity and 
cytokine action.120-121 In mice a novel isoform of SH2B2, SH2B2β, was also reported, which 
lacks a SH2 domain, dimerizes with SH2B1 and SH2B2α, and thereby inhibits cellular 
responses mediated by these genes.117 Another function of SH2B2 is the enhancement of 
Figure 10 Domain organization of human SH2B1, SH2B2, and SH2B3
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neurotrophin signaling by direct modulation of Trk receptor autophosphorylation,122 and the 
inhibition of the JAK/STAT pathway by recruitment of c-Cbl into the receptor/JAK 
complex.123-125 It was also reported that SH2B2 is expressed in brain, kidney, muscle, and 
mature B cells in spleen, and that it plays a role in signaling in B cells.126-128 
The strongest argument in favor of a role of SH2B2 in the pathogenesis of MPN is that its 
family member, SH2B3, was recently reported to be a tumor suppressor in MPN. SH2B3 
mutations were found in one patient with PMF and one with ET. These mutations were then 
transfected into Baf3 cells and were shown to exhibit JAK/STAT activation.129 In a second 
study, nine novel SH2B3 mutations were identified.130 
It was shown in SH2B3 knockout mice, that the lack of this gene leads to deregulation of 
thrombopoietin/thrombopoietin receptor signaling and similar myeloproliferative 
characteristics to those found in MPN patients. These mice display hypersensitivity to 
cytokines, increased number of in vitro multilineage (CFU-GEMM), erythroid (CFU-E), and 
megakaryocytic (CFU-MK) progenitor colonies, high platelet counts, splenomegaly, fibrosis, 
and extramedullary hematopoiesis.131-132 SH2B3 levels correlate with an increase in the  
JAK2-V617F mutant allele burden in MPN patients and its expression is regulated by the 
TPO-signaling pathway. It was also shown that there is a tighter association of SH2B3 with 
the mutated JAK2, but it is unclear how JAK2-V617F can surmount SH2B3 inhibition.133 
SH2B3-/- mice proofed that the adaptor protein is a negative regulator of cytokine signaling 
during hematopoiesis. It controls TPO-induced self-renewal, quiescence and proliferation of 
hematopoietic stem cells (HSC) and myeloid progenitors.134-137 These animals showed 
disrupted B lymphopoiesis, and abnormal megakaryopoiesis and erythropoiesis.138-140 SH2B3 
binds through its SH2 domain to JAK2 and by this means negatively modulates MPL and 
EPOR signaling. It was also shown that it binds to and regulates MPL-W515L and         
JAK2-V617F.134,141-142 
SH2B3 is located near CUX2 on chromosome 12q, showing that CUX1 with SH2B2 on 
chromosome 7q, and CUX2 with SH2B3 on chromosome 12q, could have had an important 
role during evolution, and that is why the genes got duplicated. CUX (Cut homeobox) genes 
can be found in all metazoans.143 
CUX2 (CUTL2) is a homolog of CUX1 and a regulator of dendrite branching, spine 
development, and synapse formation in the cerebral cortex. Cux2 knockout mice display 
reduced synaptic function and defects in working memory.144 It plays also a role in regulating 
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the formation of dorsal spinal cord interneurons.145 In one patient a homozygous deletion of 
CUX2 was found recently,146 which could mean that CUX family members play a role in 
MPN pathogenesis.21 
1.6 TP53 
A recent study showed that amplifications of chromosome 1q were significantly associated 
with transformation to AML. In patients with post-MPN AML 18,18% had a gain of 
chromosome 1q and it was shown that the minimal amplified region harbored MDM4.23 This 
gene is an inhibitor of p53 which is often amplified in different cancer types.147 The 
observation led to the analysis of the p53 pathway contribution in post-MPN AML. Somatic 
mutations were found in 27,3% of patients which transformed into leukemia. None of these 
patients had a gain of chromosome 1q which means that these events are mutual exclusive as 
has been also observed in some solid tumors.23,148  
1.7 Heterogeneity in MPN pathogenesis 
There are two models of MPN pathogenesis based on a single-hit or a multi-hit        
concept.12-13,28,34,149 The first 
model suggests that the acquisition 
of JAK2 mutations is the disease-
initiating event that causes the 
onset of disease phenotype and the 
clonal hematopoiesis. On the 
contrary, the second model 
assumes that there are “pre-JAK2” 
mutations that cause clonal 
hematopoiesis before the JAK2 
mutation and the onset of the 
disease phenotype (figure 11). 
Neither of the two models can be generally applied to all MPN patients because of the 
intrinsic genetic heterogeneity. This clonal diversity is due to the variability of chromosomal 
aberrations and somatic mutations present in MPN.18  
Figure 11 Two possible models of MPN pathogenesis
18
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1.8 Diagnosis 
Diagnosis of PV, ET and PMF is based on a combined evaluation of clinical and laboratory 
features (figure 12).150 One of the 
new diagnostic tools is the screening 
for the JAK2-V617F mutation with a 
sensitivity of (97%).151-152 The 
likelihood of thrombotic 
complications in PV and ET can be 
also estimated by the age of the 
patient and his history of 
thrombosis.20,153-157 Risk factors for 
shortened survival are for example 
history of thrombosis, leukocytosis, advanced age, and anemia.20,156-158  
1.9 Treatment 
The current therapy for PV, ET, and PMF is not curative. In PMF, and post-ET/PV MF 
allogeneic stem-cell transplantation (alloSCT) is potentially curative. The aim of current 
treatment in PV and ET is to prevent thrombohemorrhagic complications, and in PMF to 
reduce anemia, and splenomegaly.1 In PV patients low-dose aspirin is used, because of its 
antithrombotic effect,159 and hydroxyurea for high-risk ET.160-161  PV and ET patients who are 
either intolerant or resistant to hydroxyurea are treated with IFN-α162-163 or busulfan.164-165 
Two recent studies of pegylated INF-α reported around 80% hematologic remissions and 
decreases in JAK2-V617F allele burden.162-163 For PMF patients, the approach is to observe 
low-risk patients without any therapeutic intervention,1,154 and consider high or intermediate-2 
risk patients for investigational drug therapy or alloSCT.1 Due to the genetic heterogeneity of 
MPN, it can be difficult to cure patients with small molecule inhibitors that target           
JAK2-V617F. These drugs could cause elimination of myeloid cells positive for this 
mutation, but it is questionable, if they would restore polyclonal hematopoiesis in patients 
with high genetic and clonal diversity.18  
Figure 12 Diagnostic algorithm
1
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2 AIM OF THE STUDY 
Using 6.0 microarrays, we identified chromosomal aberrations associated with transformation 
to post-MPN AML and disease progression. Gains of chromosome 1q and 3q, deletions of 7q, 
5q, 6p and 7p, and UPDs of 19q and 22q showed significant association with post-MPN AML 
compared to chronic phase. The common deleted region (CDR), which is the minimum 
overlap of all deletions detected for a particular chromosome in a cohort, contained only the 
CUX1 gene.21 However, the neighboring gene which is only around 1kb away from CUX1, is 
SH2B2, a homolog of SH2B3 previously reported to be associated with MPN  
pathogenesis.129-130 It could still be that an enhancer region for SH2B2 is located in the CDR 
on 7q. 
In order to identify novel mutations in the candidate genes, the granulocytic DNA of            
29 patients with post-MPN AML and 3 chronic patients with del7q from three cohorts were 
sequenced.  
For the subsequent functional analysis of CUX1 and SH2B2, it was attempted to knock-down 
these genes in Baf3/EpoR cells. The growth properties of the cells were followed after the 
lentiviral delivery of shRNA pins targeting CUX1 and SH2B2. If one of the genes would be 
important for the pathogenesis of MPN, a knock down would lead to a proliferative advantage 
of these cells which would have a reduced expression of CUX1 or SH2B2. Other experiments 
were to identify how hydroxyurea treatment changes the growth dynamics of the transduced 
Baf3/EpoR cells expressing shRNA pins against CUX1 and SH2B2, and to identify 
erythropoietin sensitivity changes in these cells. 
Another gene that is associates with transformation to post-MPN AML is p53, which was 
sequenced for 24 paired samples.  
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3 MATERIALS AND METHODS 
3.1 MATERIALS 
3.1.1 Equipment 
- 3130xl Genetic Analyzer (Applied Biosystems) 
- Real-time PCR machine: 7900HT Fast Real-Time PCR System (Applied Biosystems) 
- FACS cell analyzer: BD LSRFortessaTM (BD Biosciences) 
- Thermocycler: PeqSTAR 96 Universal (peqlab) 
- Centrifuges: Eppendorf Centrifuges 3810, 5418, 5424, 5424R (Eppendorf) 
- Microcentrifuge: Galaxy MiniStar (VWR) 
- Vacuum pump: Membrane Vacuum Pump MP86 (Biometra) 
- Water bath (GFL 1002) 
- Incubator: Galaxy 170R (New Brunswick) 
- Vortex: Vortex-Genie 2 (Scientific Industries, Inc.) 
- Thermoblock: Dry Block Heating Thermostat Bio TDB-100 (A. Hartenstein) 
- Gas burner: Fuego SCS (Carl ROTH) 
- Electrophoresis power supply: Owl EC-105 Compact Power Supply (Thermo Electron 
Corporation) 
- Gel-imaging:UVsolo TS Imaging System (Biometra, An Analytik Jena Company) 
3.1.2 Plastics 
- Gel electrophoresis chamber: EasyPhor (Biozym Scientific GmbH) 
- PCR plates: Thermo-Fast® 96 non-skirted, skirted, and detection plate (Thermo 
Scientific) 
- Plates for PCR purification: MinElute 96 UF plate (Qiagen), Nunc 96-well conical 
microplate (Thermo Scientific), Millipore MultiScreen®-HV 96-well plates (Fisher 
Scientific) 
- Real-time PCR plates: MicroAmp Fast Optical 96-well Reaction Plate with Barcode 
(Applied Biosystems) 
- Tips: TipOne® Filter Tips 10µL, 20µL, 100µL, 200µL, 1000µL (Starlab) 
- Pipettes: 2mL, 5mL, 10mL, 25mL (Greiner bio-one) 
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- Tubes: 15mL and 50mL conical tubes (Sarstedt), 15mL and 50mL polypropylene 
conical tubes (BD Falcon), 14mL polypropylene round bottom tubes (BD Falcon) 
- Microcentrifuge tubes: 1.5mL, 2mL, black 1.5mL (Eppendorf) 
- Culture plates: 6-well tissue culture plate, flat bottom, with low-evaporation lid (BD 
Falcon), MicrotestTM tissue culture plate 96-well, flat bottom, with low-evaporation lid 
(BD Falcon) 
- Culture dish: Cell Culture Dish 100x20mm (Corning) 
- Petri dish: 100x15mm (BD Falcon) 
- Cryogenic vials (Corning) 
- Syringes: 500µL, 12.5mL (Eppendorf) 
3.1.3 Materials for working with DNA/RNA 
- PCR mix: AmpliTaq Gold® DNA Polymerase + buffer + MgCl2 (Applied 
Biosystems), AmpliTaq® 360 master mix + 360 enhancer (Applied Biosystems) 
- dNTP mix (Fermentas)  
- Tris 5mM: diluted Tris 1M pH 7.5 (Amresco) 
- Big Dye: BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) 
- Agarose: StarPure Agarose Low EEO Standard (Starlab) 
- DNA ladder: DirectLoadTM Wide Range DNA Marker (Sigma-Aldrich) 
- Ethidium bromide (Oncor) 
- Gel extraction: peqGOLD Gel Extraction Kit (Peqlab) 
- Sephadex: SephadexTM G-50 Superfine (GE Healthcare) 
- Formamide: Hi-DiTM formamide (Applied Biosystems) 
- RNA preparation: TRIzol® reagent (Invitrogen) 
- Chloroform (Merck Chemicals) 
- DNA purification: Wizard® Genomic DNA purification kit (Promega) 
- Isopropanol: 2-Propanol für die Molekularbiologie (AppliChem) 
- Ethanol: Ethanol absolute for analysis Emsure® (Merck Chemicals) 
- Mini prep: QIAprep Spin Miniprep Kit (Qiagen) 
- Maxi prep: PureYieldTM Plasmid Maxiprep System (Promega) 
- Restriction enzymes: XhoI, EcoRI (New England BioLabs) 
- Buffer for restriction: NEBuffer 2 (New England BioLabs) 
- BSA: 10xBSA (New England BioLabs) 
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- Ligase: T4 DNA Ligase + 10x Reaction Buffer (New England BioLabs) 
- Reverse transcriptase: MultiScribeTM Reverse Transcriptase (Applied Biosystems) 
- Real-time PCR: SYBR Green PCR Master Mix (Applied Biosystems), TaqMan® Gene 
Expression Master Mix (Applied Biosystems) 
3.1.4 Buffers and solutions 
- 10xTBE pH ~8.0: 
890mM boric acid (Life Technologies) 
890mM Tris (Invitrogen) 
20mM EDTA-Na2.2H2O (USB) 
- DNA loading dye: 
0.25% bromophenol blue (Sigma-Aldrich) 
30% glycerol in H2O (Sigma-Aldrich) 
- 2xHBS buffer pH 7.04: 
280mM NaCl (Sigma-Aldrich) 
10mM KCl (Sigma-Aldrich) 
1.5mM Na2HPO4.2H2O (Merck Chemicals) 
12mM D(+)-Glucose (Merck Chemicals) 
50mM HEPES (Roche Applied Science) 
3.1.5 Materials for blood preparation 
- Histopaque: Histopaque®-1077 (Sigma-Aldrich)   
- DPBS: Dulbecco’s Phosphate-Buffered Saline (Invitrogen) 
3.1.6 Media 
- DMEM (Dulbecco’s phosphate buffered saline, Invitrogen) 
Supplements: 10% FBS (Gibco® Fetal Bovine Serum, Invitrogen) 
1% penicillin/ streptomycin (Invitrogen) 
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- IMDM (Iccove’s modified Dulbecco’s medium, Invitrogen) 
Supplements: 10% FBS (Gibco® Fetal Bovine Serum, Invitrogen) 
  1% penicillin/ streptomycin (Invitrogen) 
  1U/mL recombinant erythropoietin (ERYPO, Janssen-Cilag Pharma) 
- S.O.C. medium (Invitrogen) 
3.1.7 Other materials 
- CaCl2 (Sigma-Aldrich) 
- Competent cells: XL10-Gold Ultracompetent cells + β-mercaptoethanol (Agilent 
Technologies), DH5α competent cells 
- Hygromycin (Invitrogen) 
- DMSO: Dimethyl Sulfoxide (Sigma-Aldrich) 
- LB Medium (MP Biomedicals) 
- Bacto agar (DIFCO) 
 
3.2 METHODS 
3.2.1 Patient cohort 
In the study 6 patients from Vienna (Austria), 19 from Pavia (Italy), and 7 from Florence 
(Italy) were included. Blood samples were collected after written informed consent of the 
patients.  
3.2.2 Blood preparation and DNA purification 
For blood preparation, two tubes with 7,5mL of patient blood each were used. At the 
beginning, two tubes with 300µL blood sample were prepared for whole genome DNA 
purification and storage. The tubes with the remaining blood were centrifuged at 99g for      
10 minutes without brake. After the centrifugation, the buffy coat with leucocytes, which lies 
between the serum and the erythrocytes, was taken up with a pipette with circling movements 
and then diluted in PBS. To isolate the mononuclear cells (MNCs) and the granulocytes, 5mL 
of Histopaque®-1077, which allows a density gradient centrifugation, was put into new tubes 
and on top of it, 5mL of the buffy coat fraction was carefully placed. After centrifugation of 
the tubes for 30 minutes at 400g with no brake, the erythrocytes went through the gradient 
and accumulated at the bottom, above which a layer of granulocytes formed, then the 
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Histopaque®-1077 and above, the MNCs and plasma were concentrated. Afterwards, plasma 
and MNCs were put in one tube, the Histopaque®-1077 was discarded and granulocytes with 
the erythrocytes were put in another tube. The MNCs were washed twice with PBS (5-10mL) 
and centrifuged for 10 minutes at 250g with brake 5, and in the tube with granulocytes and 
whole genome DNA, the erythrocytes were lysed with cell lysis buffer (~50mL). During cell 
lysis the content changed after 10 minutes from red and turbid to dark red and clear. 
Following centrifugation for 10 minutes at 250g (1 minute at 14.000g for whole genome 
DNA), the supernatant was removed, and the pellet was washed with 10mL (1mL) PBS. After 
the second washing and centrifugation, the pellet was vortexed to loosen it from the bottom of 
the tube. 
For DNA purification, the nuclei lysis solution from the Promega Wizard® Genomic DNA 
Purification Kit was added to the probes (2mL, and 300µL for whole genome DNA) and left 
overnight at room temperature. Then the protein precipitation solution was added (660µL; 
100µL), and the samples were vortexed for 20 seconds. Afterwards, the whole genome DNA 
sample was centrifuged at 14.000rpm for 1 minute and the others at 2000g for 10 minutes. 
Subsequently, the supernatant was put into a new tube with isopropanol (2mL; 300µL), and 
the probes were mixed by inversion. Then they were centrifuged as before. After that,       
70% ethanol (2mL; 300µL) was added to the pellet for washing, and the probes were again 
centrifuged. In the end, the ethanol was aspirated and the pellet air-dried. Then the DNA was 
rehydrated in DNA rehydration solution (300µL; 100µL). After 1h at 65°C or overnight at 
4°C, the DNA concentration was measured using Nanodrop. 
3.2.3 Microarray genotyping 
Microarray genotyping was performed on genomic DNA from peripheral blood granulocytes, 
based on the fact that the phenotypic effect is mostly seen in the myeloid lineage, to which 
granulocytes belong to. Microarray genotyping was done using the Genome-Wide Human 
SNP 6.0 arrays (Affymetrix) according to the manufacturer’s protocols. Evaluation of copy 
number and loss of heterozygosity (LOH) was perfomed by the Genotyping Console version 
3.0.2 software (Affymetrix).  
29 
 
3.2.4 Sequencing 
PCR reactions were performed with the PeqSTAR thermocycler using 10xAmpliTaq GOLD® 
buffer, 25mM MgCl2, 2,5mM dNTPs, 10µM forward primer, 10µM reverse primer,          
50% DMSO, AmpliTaq GOLD® Polymerase 5U/µL, template, and ddH2O, or AmpliTaq® 360 
master mix, 360 GC enhancer, 10µM forward primer, 10µM reverse primer, template, and 
ddH2O for GC-rich DNA sequences.  
PCR master mix with AmpliTaq 
GOLD
®
 
volume [µL] 
for 1 reaction 
  
  
10xAmpliTaq GOLD
®
 buffer 2,0 
PCR master mix with 
AmpliTaq
®
 360 
volume [µL] 
for 1 reaction 
25mM MgCl2 1,2 AmpliTaq
®
 360 master mix 10,0 
2.5 mM dNTPs 1,6 360 GC enhancer 2,0 
10µM forward primer 0,7 10µM forward primer 0,8 
10µM reverse primer 0,7 10µM reverse primer 0,8 
AmpliTaq GOLD
®
 polymerase 5U/µL 0,1 10ng/µL DNA  2,0 
10ng/µL DNA  2,0 ddH2O 4,4 
ddH2O 11,7 
 
20,0 
 
20,0 
  
Table 1 PCR master mix 
 
PCR touchdown program 
95°C 5' 
 94°C 30'' 
10 cycles 67°C-57°C 30'' 
72°C 30'' 
94°C 30'' 
26 cycles 57°C 30'' 
72°C 30'' 
72°C 10' 
 4°C ∞ 
 
                                                                                    Table 2 PCR cycling conditions 
 
Verification of PCR reactions was performed on 1,5% agarose gels which were run for         
25 minutes at 120V. 1µL ethidium bromide per 100mL agarose gel was used (0,01µL/mL).  
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For removal of unincorporated dNTPs and primers, 50µL ddH2O were added to the PCR 
products and then they were transferred carefully into a QIAGEN MinElute 96 UF Plate. The 
plate was placed on a vacuum manifold and the vacuum was turned on to a maximum of 
800mbar until the wells were dry. The wells were washed twice by adding 60µL ddH2O. 
After the third washing and drying, the plate was sealed at the bottom with aluminum sealing 
foil to avoid leaking. 20µL of 5mM Tris pH 7.5 were added to the wells to resuspend the PCR 
products, and then the plate was sealed. Incubation was made by shaking the plate on a vortex 
(speed 3 for 10 minutes). Afterwards the probes were transferred to a non-skirted PCR plate. 
Subsequently, the BigDye reaction was prepared in order to add fluorescent dNTPs to the 
purified PCR products.  
BigDye
®
 master mix 
volume [µL] 
for 1 reaction 
    5xBigDye
®
 sequencing buffer 1,0 
 
96°C 1' 
 BigDye
®
 Terminator v3.1 0,5 
 
96°C 10'' 
25 cycles 10µM primer 1,0 
 
50°C 5'' 
DNA 7,0 
 
60°C 4' 
ddH2O 0,5 
 
4°C ∞ 
 
 
10,0 
    
                Table 3 BigDye master mix for sequencing, and thermal cycling conditions 
 
10µL ddH2O were added to each BigDye sequencing product. The blue Centrifuge Alignment 
Frame was placed on the top of a v-bottom collection plate, and then the HV plate was placed 
on the assembly. 250µL of 6% (w/v) Sephadex G-50 gel were distributed with a stepper 
pipette per well, and the lid was closed. The plate was centrifuged at 910g for 5 minutes to 
pack minicolumns and then the flow-through was discarded. This step was repeated one more 
time. A clean v-bottom collection plate was adapted under the HV plate. 20µL of sequencing 
reactions were added carefully to the center of each well and centrifuged 910g for 5 minutes. 
10µL of Hi-Di Formamide were added per well to a 96-well detection plate for the 3130xl 
sequencer. 2µL of the purified products were transferred per well. Septa were adapted on the 
plate and the plate was spun down. The samples were denatured for 2 minutes at 98°C, and 
then placed on ice for 2 minutes. After that, the plates were placed on the 3130xl plate 
assembly for their sequencing.  
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CUX1 Forward Reverse Product size
Exon1 CCTCCTGGCGGCTCCTGAAC GAGGGACTCGGCCCCGACTC 294bp
Exon2 CTGGTCAAATGCAAATAGGA CCAGCATTCTAAGATCCCTT 241bp
Exon3 AATTAGCACTGACTGCCACG CACCATCTGGGCAGCAC 258bp
Exon4 TCTAAGAGGCTGAAGCCCAG GGAAGTTGCCACTGATGGTG 335bp
Exon5 GAGCTGATGTCCCAGGAGC AGCTGGTCTCAAAAGTATGGG 332bp
Exon6 AACACACCGATCCTACCAGG TGGGCTTATTTTGCAGATCC 321bp
Exon7 ACAAAGTTGGGGTGTGGAAG GAAGAGCAACAGGTATCCGC 366bp
Exon8 CTCCTCACAGAAATCTTTGCC CAGCACAGAGGTCAAGAACC 267bp
Exon9 CGAGCCCTGAGCTAGGAAG AAAATGGAAGGATAACCGGC 246bp
Exon10 TCATAATCGCTCAATTATTTCTTCC CAATTGGTCAAAGCAAACCC 464bp
Exon11 CACCATCCACACACTGACATC CAAGTCCAGAAAGGCAGAGG 396bp
Exon12 CGTTGACTCCATTCGCAAG ATTTACGGGCATCTGCTGAG 315bp
Exon13 AGAAAATAATCACTCTGGTGGC TTTTGGTAGTGCCCATCTCC 661bp
Exon14 ACAGATGGAGGGAGGCAGG TGCATCTGTCCAGACTCACG 286bp
Exon15 CAGACCGTGGGTTGGAGAG TCACCAGCTGCCTGATACAC 324bp
Exon16 CACTCCTTGCCACACCCAC GGAAGGGACTACTCTTTGGGG 271bp
Exon17 CTTCTACCCCATGGCATTTG TCTGTGCCACATCTCTCTCC 320bp
Exon18 ATCCCTGACTTCTGCCTGTG GGCTCCACTCTGTGAGCTTC 497bp
Exon19 CCAGCCACATTCACATTGTC TACATTGCACTGAAGCGGTG 489bp
Exon20 GAGTAGACTGTGCACCCAGG GACCCTGTCCCAGATCACAC 366bp
Exon21 CACCCTAGGGCCCTTTCTG AGAGATGCAGCTTGGGGTAG 288bp
Exon22-23 ACATGTCTAAGACCCACCCG AGCGGATAAGGGCAGTTTC 631bp
Exon1a AGCGGCGCACCCTTAGGGTC CACCAGGCCGCCCTAGAGCA 222bp
Exon15a_1 TTTGTTTTCCCTTTTGCGG TCCCAGCACTTTCTGACTGG 511bp
Exon15a_2 CTCCAAGGCTATGCAGGAAG GCACAAATGTTTCATCACGC 522bp
Exon16a TCTTTAGTGACAGGCGGCTC GTTCCAGGCCAGAATCACAC 275bp
Exon17a ATCTGCCTCCTTGTGTCACC CGTGCCTAAATGCTTGAGAAC 356bp
Exon18a_1 CCCACACTTTGCAGTAGGTC TTTCACCTGTCTCAGGACCC 466bp
Exon18a_2 ACCTCTCGCCATCTCCCTG GTTCTGTGGTGTCTCGCTGC 451bp
Exon18a_3 AGAAGAAATGCCGCCTCCTC CTTGGGTGAATTGAAATGGG 521bp
Exon19a CAGAAGTCAGCCCTAGACGC CTCCCTCTCTGCATAGCCC 369bp
Exon20a GAAACCTTTCACCTGCTCCC CACTGTCAGCTCGCTCTCC 439bp
Exon21a CCGTCTGCTTCTCCTACAGAG ACTCTGTGGTTGGCTTGGC 513bp
Exon22a CCCTGAGCCTTTAAACTCCTG ATGGGTCAATGTCCCTCATC 399bp
Exon23a TGCTCTATGCAAAGTCCTGC AAGGAACGGACCAATCACC 516bp
Exon24a_1 TGGAGAATAGGGGAGTGGTG CTGCTGCTGCTGTTGCTG 690bp
Exon24a_2 GAGGACGCCGCTACCTCAGC GACCCCGTCCAGGCCCTTGC 324bp
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                   Table 4 Primer sequences for CUX1, SH2B2, SH2B3, and TP53, used for exon sequencing 
3.2.5 Cloning of shRNA pins 
Six shRNA constructs targeting CUX1, five shRNAs against SH2B2, and a scrambled 
oligonucleotide for each gene as a control were designed for ligation into the SFLV vector 
(kindly provided by Lenhard Rudolph from the Ulm University). The vector carries resistance 
genes against ampicillin and hygromycin, and GFP, BFP, or RFP as fluorescent markers.  
 
                                      Figure 13 SFLV vector with BFP or RFP marker and XhoI and EcoRI restriction sites 
SH2B2 Forward Reverse Product size
Exon1 CCACAGCCACTTCCACATC CCCGAGAGTGGGAGAAAGG 283bp
Exon2_1 CACACAGCCCCAGAGAGTC CACGCACAGGCTCATGTTG 560bp
Exon2_2 CCAACTTCCTGGACGTCTTC TGGCACCAAATACTTCACCC 663bp
Exon3 GAGGGCCACTCTAACACCTG GTCCTGCCTTAGGCTCCTTC 301bp
Exon4 ATCAGCCATTTGAGCCACTC ATTTCTCAAGCTGAGCTCCC 291bp
Exon5 GAGGTTACAGTCAGCCACCG GTGATGTGTAGGAGGGACGC 630bp
Exon6 GAGCCTTGGTCCTTCCATC CTGAGGCTATGGGACAGGAG 376bp
Exon7 TGCAACTCGGAAACCTGAG GTGGGAGAAAGGACGACAG 553bp
SH2B3 Forward Reverse Product size
Exon2_2 GCTCCTTCCAGCACTTTCG CTGGAAAGCCATCACACCTC 431bp
TP53 Forward Reverse Product size
Exon1-2 TCTCAGACACTGGCATGGTG TGGGTGAAAAGAGCAGTCAG 449bp
Exon3 CGTTCTGGTAAGGACAAGGG GAAGAGGAATCCCAAAGTTCC 489bp
Exon4-5 GCATGTTTGTTTCTTTGCTGC CATGGGGTTATAGGGAGGTC 588bp
Exon6 GTGCTGGGCACCTGTAGTC AGCAGTAAGGAGATTCCCCG 482bp
Exon7-8 TGGTTGGGAGTAGATGGAGC GCCCCAATTGCAGGTAAAAC 492bp
Exon9 TGCCGTTTTCTTCTTGACTGT GCAGGCTAGGCTAAGCTATGA 334bp
Exon10 TGCATGTTGCTTTTGTACCG AGCTGCCTTTGACCATGAAG 316bp
Exon11 ATTTGAATTCCCGTTGTCCC GCAAGCAAGGGTTCAAAGAC 292bp
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Table 5 shRNAs used for CUX1 and SH2B2 knock down 
 
At the beginning, maxipreps were performed with the PureYield Plasmid Maxiprep System 
for obtaining SFLV-BFP and SFLV-RFP vectors. For this, a colony was inoculated in 2mL of 
LB+Amp medium and left overnight at 37°C for shaking at 220rpm. After 8 hours, 500µL of 
the pre-inoculation was put into 180mL of LB+Amp medium and left again overnight at 37°C 
at 220rpm. Afterwards, the tubes were centrifuged for 10 minutes at 6.000g, and the pellet 
was resuspended in 12mL of the resuspension solution. The obtained solution was put into a 
50mL Falcon tube and 12mL cell lysis solution was added. The tubes were inverted gently 
and then, 12mL of the neutralization solution was added. The tubes were centrifuged at 
14.000g for 20 minutes, and the DNA was purified. For this, the solution was poured into a 
column and placed on a vacuum. The vacuum was opened, and after drying, 5mL of the 
endotoxin removal wash was added. Then, the columns were placed into 50mL Falcon tubes, 
1,5mL ddH2O were added to each, and they were spun down at 2.000g for 5 minutes for DNA 
elution. After that, the concentration of the vector DNA was measured using Nanodrop. 
 The vectors were digested using XhoI and EcoRI restriction enzymes. The 
digestion mix was left at 37°C for 2-3h. Afterwards, an 0,8% agarose gel 
was prepared with 1µL ethidium bromide per 100mL agarose and left 
running for around 1h at 80-90V. The undigested vectors were used as 
control. Later, the bands with the digested vectors were cut out under UV 
light and gel extraction with the peqGOLD Gel Extraction Kit was 
performed. For this, equal volume of binding buffer was added to each gel 
slice and incubated for 7 minutes at 55°C-65°C. The mixture was vortexed 
every 2-3 minutes until the agarose was completely dissolved. The samples 
Sequence 5' to 3' Overhang Code
forward TCGAACCAGCGCATCTTCGGACATTATAGTGAAGCCACAGATGTATAATGTCCGAAGATGCGCTGGC XhoI
reverse AATTGCCAGCGCATCTTCGGACATTATACATCTGTGGCTTCACTATAATGTCCGAAGATGCGCTGGT EcoRI
forward TCGACGCCAAGAATAGCACACTCAAATAGTGAAGCCACAGATGTATTTGAGTGTGCTATTCTTGGCA XhoI
reverse AATTTGCCAAGAATAGCACACTCAAATACATCTGTGGCTTCACTATTTGAGTGTGCTATTCTTGGCG EcoRI
forward TCGAGCCAAGAATAGCACACTCAAACTCGAGTTTGAGTGTGCTATTCTTGGCTTTTTG XhoI
reverse AATTCAAAAAGCCAAGAATAGCACACTCAAACTCGAGTTTGAGTGTGCTATTCTTGGC EcoRI
forward TCGAGCAGCTCATCAAGCACAACATCTCGAGATGTTGTGCTTGATGAGCTGCTTTTTG XhoI
reverse AATTCAAAAAGCAGCTCATCAAGCACAACATCTCGAGATGTTGTGCTTGATGAGCTGC EcoRI
forward TCGACCACTGCTAAAGAGCTTCCAACTCGAGTTGGAAGCTCTTTAGCAGTGGTTTTTG XhoI
reverse AATTCAAAAACCACTGCTAAAGAGCTTCCAACTCGAGTTGGAAGCTCTTTAGCAGTGG EcoRI
forward TCGAGCCCTCAGCATCCAAGAATTACTCGAGTAATTCTTGGATGCTGAGGGCTTTTTG XhoI
reverse AATTCAAAAAGCCCTCAGCATCCAAGAATTACTCGAGTAATTCTTGGATGCTGAGGGC EcoRI
forward TCGAGACTCCACGAATCATATTAGACTCGAGTCTAATATGATTCGTGGAGTCTTTTTTG XhoI
reverse AATTCAAAAAAGACTCCACGAATCATATTAGACTCGAGTCTAATATGATTCGTGGAGTC EcoRI
forward TCGACCACTCCCATTAGCAGCTATTCTCGAGAATAGCTGCTAATGGGAGTGGTTTTTG XhoI
reverse AATTCAAAAACCACTCCCATTAGCAGCTATTCTCGAGAATAGCTGCTAATGGGAGTGG EcoRI
forward TCGACGGCTGATATCACCCTAAGAACTCGAGTTCTTAGGGTGATATCAGCCGTTTTTG XhoI
reverse AATTCAAAAACGGCTGATATCACCCTAAGAACTCGAGTTCTTAGGGTGATATCAGCCG EcoRI
forward TCGAGAGCAGAATACATCCTGGAAACTCGAGTTTCCAGGATGTATTCTGCTCTTTTTG XhoI
reverse AATTCAAAAAGAGCAGAATACATCCTGGAAACTCGAGTTTCCAGGATGTATTCTGCTC EcoRI
forward TCGAGATCGGCTGATATCACCCTAACTCGAGTTAGGGTGATATCAGCCGATCTTTTTG XhoI
reverse AATTCAAAAAGATCGGCTGATATCACCCTAACTCGAGTTAGGGTGATATCAGCCGATC EcoRI
forward TCGAGTGGAGAATCAGTACTCCTTTCTCGAGAAAGGAGTACTGATTCTCCACTTTTTG XhoI
reverse AATTCAAAAAGTGGAGAATCAGTACTCCTTTCTCGAGAAAGGAGTACTGATTCTCCAC EcoRI
forward TCGAGTCCTATCAATCCCCCTACATCTCGAGATGTAGGGGGATTGATAGGACTTTTTTG XhoI
reverse AATTCAAAAAAGTCCTATCAATCCCCCTACATCTCGAGATGTAGGGGGATTGATAGGAC EcoRI
TRCN0000100119
TRCN0000100118
TRCN0000100117
TRCN0000100116
TRCN0000100115
TRCN0000070558
TRCN0000070559
TRCN0000070560
TRCN0000070561
Scramble
CUX1
SH2B2
shRNA_1
shRNA_2
shRNA_3
shRNA_4
shRNA_5
shRNA_6
Scramble
shRNA_1
shRNA_2
shRNA_3
shRNA_4
shRNA_5
Table 6 Master mix for 
vector restriction (for 1 
reaction) 
Buffer 2 2,0 
XhoI 0,5 
EcoRI 0,5 
10xBSA 2,0 
8µg DNA  1,0 
ddH2O 14,0 
 
20,0 
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were loaded into a column and centrifuged for 1 minute at 10.000g. After that, they were 
washed once with 300µL binding buffer and twice with 600µL CG wash buffer, incubated    
2-3 minutes and centrifuged each time as before. As the next step, a centrifugation for            
1 minute at 10.000g was performed for drying the column. Elution was done by addition of 
50µL elution buffer and centrifugation for 1 minute at 5.000g. 
Subsequently, in order to anneal the forward and reverse shRNA sequence, 1µL of each 
10µM oligonucleotide was mixed with 5µL of NEB2 buffer and 43µL ddH2O (end 
concentration was 200nM). Then the mixture was cooled down 1°C every 4 minutes from 
96°C to 4°C. 
The ligation of the annealed shRNAs with the appropriate vector was done at room 
temperature for 2-3h using the NEB ligase. Different dilutions of the inserts were used.  
10xbuffer 1,0 
100ng vector 1,1 
insert 1,0 
NEB ligase 0,5 
ddH2O 6,4 
 
10,0 
                                                                       Table 7 Master mix for ligation (for 1 reaction) 
 
For transformation, XL10-Gold Ultracompetent Cells were used. Two 14-mL round-bottom 
tubes were pre-chilled on ice, and the S.O.C. medium was pre-heated to 42°C. The cells were 
thawed on ice, gently mixed and aliquots of 100µL were made in the pre-chilled tubes. 4µL of 
a β-mercaptoethanol mix were added to each tube. The tubes were swirled gently and the cells 
were incubated on ice for 10 minutes, swirling every 2 minutes. Afterwards, 2µL of the 
ligation mixture were added to the tubes and then incubated on ice for 30 minutes. The tubes 
were heat-pulsed in a 42°C water bath for 30 seconds and then incubated on ice for 2 minutes. 
900µL of the pre-heated S.O.C. medium was added to the tubes, which were then incubated at 
37°C for 1 hour with shaking at 200rpm. After that, the cells were plated on LB+Amp plates, 
and incubated at 37°C overnight.  
Afterwards, one colony was inoculated in 2mL of LB+Amp medium each and left at 37°C 
overnight shaking. Then, miniprep was performed with the QIAprep Spin Miniprep Kit to 
obtain the vectors. For this, the overnight culture was centrifuged at 6.800g for 3 minutes, and 
then the pellet was resuspended in 250µL buffer P1, 250µL of buffer P2 was added and mixed 
by inverting the tube. After that, 350µL of buffer N3 was added and mixed by invertion, and 
then the tubes were centrifuged for 10 minutes at 17.900g. Subsequently, the supernatant was 
transferred to a column which was centrifuged for 30 seconds. 500µL of buffer PB was added 
and again the column was centrifuged. The second washing was done by addition of 750µL 
buffer PE. Another centrifugation was made afterwards for removal of the residual wash 
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buffer. Afterwards, the columns were placed in Eppendorf tubes, and 50µL of buffer EB was 
added for elution of DNA. The concentration was measured by Nanodrop. 
Sequence verification was made by performing BigDye reaction with 150ng of vector DNA 
and two different primers (forward TGTTTGAATGAGCTTCAGTACTTTACAG, reverse 
AGTGATTTAATTTATACCATTTTAATTCAGCTTTG). 
BigDye
®
 master mix 
volume [µL] 
for 1 reaction 
    5xBigDye
®
 sequencing buffer 1,0 
 
96°C 1' 
 BigDye
®
 Terminator v3.1 1,0 
 
96°C 10'' 
25 cycles 10µM primer 1,0 
 
50°C 5'' 
DNA 150ng 
 
60°C 4' 
ddH2O 7-150ng of DNA 
 
4°C ∞ 
 
 
10,0 
     
                Table 8 BigDye master mix for shRNA verification, and thermal cycling conditions 
 
For obtaining the required amount of DNA needed for transfection, transformation of DH5α 
competent cells (made competent using MgCl2 and CaCl2) was made with the final constructs. 
3-4 minipreps were performed per pin to obtain enough DNA for the subsequent transfection 
of 293T cells. 
3.2.6 Transfection of 293T cells for virus production 
293T cells were splitted a day before transfection, and 1-3h before transfection, the medium 
(DMEM+10%FBS+1%P/S) was changed. 2xHBS buffer with pH 7.04, filter sterilized before 
use, was used for transfection. First, a 15mL Falcon tube was prepared with 500µL HBS and 
an Eppendorf tube with the vector mix, which consisted of 15µg vector DNA, 10µg DR8.91, 
3µg VSV.9, 60µL 2M CaCl2, and filtered H2O up to 500µL. The HBS was bubbled and the 
vector mix was added drop-wise to the buffer. After 20 minutes at room temperature, the mix 
was dropped to the cells. After 12h the medium was changed to 3mL and after 12h more, the 
supernatant with the virus was taken up with a syringe and was replaced with fresh medium. 
After another 24h, the supernatant was collected again and used for infections. Virus was 
stored at -80°C.  
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3.2.7 Viral transduction of Baf3/EpoR cell line 
Baf3/EpoR cells, which are an erythropoietin dependent, immortalized murine bone marrow-
derived pro-B cell line, were transduced in 24-well, or 96-well plates, using two different 
schemes. One was a 12h incubation, and the other spin infection consisting of a centrifugation 
for 2h at 1000g. Two different dilutions of the viral supernatant were tested, 1:4, and 1:2. The 
medium (IMDM+10%FBS+1%P/S+1:10.000Epo) was changed after 12h. 
3.2.8 FACS 
In order to check the transfection efficiency, FACS measurement was performed using the 
LSR Fortessa FACS machine, and the data was analyzed using the FACS Diva software.  
3.2.9 Knock-down efficiency measurement by qPCR 
The efficiency of knock-down was controlled by comparing the target mRNA level of 
knocked-down cells to the one of the control cells by real time PCR performed with a 
7900HT Real Time PCR System. Each mRNA level was normalized to the mRNA level of   
β-actin (mouse).  
For RNA extraction, 500µL of cells were put in an Eppendorf tube and centrifuged at 675g 
for 5 minutes. Afterwards, the cell pellet was resuspended in 250µL Trizol and incubated       
5 minutes at room temperature. Then, 50µL chloroform were added to each tube, which were 
vortexed for 15 seconds, and centrifuged at 12.000g for 15 minutes at 4°C. Afterwards, the 
upper layer with the RNA was separated and transferred to a new tube with 125µL of 
isopropanol. After that, the samples were incubated for 10 minutes at room temperature and 
centrifuged again as before. Subsequently, the supernatant was removed, the pellet washed 
with 1mL 75% ethanol, and then centrifuged at 7.500g for 5 minutes at 4°C. Later, traces of 
ethanol were removed, the RNA pellet was left for 5 minutes to dry, and then it was 
resuspended in 30µL ddH2O (10 minutes at 60°C). RNA was quantified using Nanodrop. 
For cDNA preparation, the master mix, consisting of a reverse transcription buffer, dNTP 
mix, random primers, ddH2O, and a reverse transcriptase was prepared on ice, and then 10µL 
of it were added to each well with 10µL of RNA (500ng). After centrifugation, the plate was 
put into the thermal cycler. 
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volume [µL] 
for 1 reaction 
   10xRT buffer  2,0   
  25xdNTP mix (100mM) 0,8 
 
25°C 10' 
10xRT random primers 2,0 
 
37°C 120' 
MultiScribe
TM
 reverse transcriptase 1,0 
 
85°C 5' 
ddH2O 4,2 
 
4°C ∞ 
500ng RNA 10,0 
   
 
20,0 
   
                     Table 9 Master mix for reverse transcription, and thermal cycling conditions 
 
For real time PCR, either the SYBR green buffer, primers, cDNA and ddH2O were mixed for 
quantification of CUX1 knock down, or the TaqMan master mix for mouse actin, TaqMan 
buffer, the cDNA, and ddH2O for actin expression measurement. 
mCux1 volume [µL] 
 
mActin volume [µL] 
2xSYBR® Green buffer 5,0 
 
TaqMan buffer 5,0 
10µM forward primer 0,4 
 
mActin TaqMan master mix 0,4 
10µM reverse primer 0,4 
 
cDNA 1,0 
cDNA 1,0 
 
ddH2O 3,6 
ddH2O 3,1 
  
10,0 
 
10,0 
   
Table 10 Real time PCR master mix for Cux1 and actin 
 
Cux1 5' to 3' sequence product size 
Forward CAAGGGGAGATTGATGCACT 149bp 
Reverse TCGTGTAGACGCTGCACTTT 
 
Table 11 Primer sequences for Cux1 for real time PCR 
 
In order to obtain cells with about 100% transduction efficiency, they were grown for about   
2 weeks in medium with addition of hygromycin, which should lead to the enrichment of cells 
having the SFLV vector integration.  
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4 RESULTS 
4.1 Sequence analysis  
CUX1 and SH2B2 deletions were found in MPN patients using Genome-wide Human SNP 
6.0 arrays (Affymetrix) and gene copy number analysis. UPDs, resulting from mitotic 
recombination, were also found with this method, using SNP analysis. Regions, in which only 
one version of a SNP was found, indicated an UPD. Resulting from an analysis of about     
444 patients’ DNA,21 30 cytogenetic aberrations were found, containing either the CUX1 and 
SH2B2 gene, or, as was the case for one patient which carried the smallest deletion, only 
CUX1 (figure 14-15). From the cohort of patients which developed post-MPN AML,            
11 deletions of chromosome 7q were identified, and in this case, the CDR comprised both 
genes, CUX1, and SH2B2 (figure 16-17). 
 
 
Figure 14 Deletions (red), gains (green), and UPDs (blue), found in all patients using 6.0 arrays  
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Figure 15 Enlargement of the CDR for depiction of genes located in this region 
 
 
Figure 16 Deletions (red), gains (green), and UPDs (blue), found in patients with post-MPN AML using 6.0 arrays 
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Figure 17 Enlargement of the CDR for depiction of genes located in this region 
 
Based on the finding from the analysis of the samples with 6.0 arrays, deletions of 
chromosome 7q are associated with transformation to post-MPN AML (figure 4).21 
Granulocytic DNA (GD) from 32 transformed patients, of which 5 carried a deletion on 7q, 
was sequenced. For validation of 
mutations, sequences of granulocytic DNA 
were compared to sequences of buccal 
DNA (BU), which is the best suited control 
DNA, or with DNA from T cells (TD) or 
monocytic cells (MD). This comparison 
was performed after verification of the 
mutation in SNP databases 
(genome.ucsc.edu, www.ensembl.org) to have confirmation that it is not a known 
polymorphism. For CUX1, 23 exons of one 
splicing variant, and 11 more of another 
variant, were sequenced. Exon 14 could not 
be sequenced, also after using the 360 GC 
enhancer for sequencing of GC-rich 
sequences, but sequencing of the other exons 
in all mentioned above patients didn’t reveal 
any somatic mutation. Only two germline 
mutations (figure 18-19) were found, which 
however, in accordance to the hypothesis of 
cancer development, don’t play a role in the 
pathogenesis of MPN.166 Due to the fact that 
SH2B2 is located only  ~1kb away from CUX1, and belongs to one gene family with SH2B3, 
the 7 exons of SH2B2 were also sequenced. One somatic mutation in exon 2 of the SH2B2 
Figure 19 Germline mutation of CUX1, found in a patient with 
post-MPN AML 
Figure 18 Germline mutation of CUX1, found in a patient 
with a deletion of chromosome 7q 
GD 
TD 
GD 
BU 
MD 
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gene was validated by sequencing T-cell DNA (figure 20). The mutation is a cytosine to 
adenosine substitution which leads to an amino acid change of glycine to cysteine at    
position 113. The Polyphen prediction is possibly damaging with a PSIC score of 1,944. 
Apart from sequencing these two genes, located in the CDR of MPN patients analyzed by   
6.0 arrays, exon 2 of SH2B3, reported to be mutated in MPN patients, was also   
sequenced.129-130 In our cohort no mutation in SH2B3 was found. 
 
                                           Figure 20 Somatic mutation in SH2B2 found in a patient with post-MPN AML  
4.2 Functional analysis 
Based on the sequencing data of CUX1 and SH2B2, an experiment was designed to test the 
functional impact of these two genes on the pathogenesis of MPN. Because of the somatic 
mutation in SH2B2, which was found in one patient, and no mutation found in CUX1, but 
occurrence of only this gene in the CDR of chromosome 7q, shRNAs were designed against 
both genes. shRNAs were cloned into a lentiviral vector for their delivery to Baf3/EpoR cells. 
To test the vectors, 293T cells were transfected only with the SFLV vectors with different 
fluorescent markers, but without any shRNA and without producing virus. We used different 
combinations of the markers to see if double and triple transfected cells, can be individually 
detected using the FACS machine, and if cells containing one, two, or three different markers, 
can be distinguished from another. On the figures one can see that double and triple 
transfected cells can be detected, as well as cells transfected with only one or another marker 
(figure 21). On one picture one can also distinguish double transfected cells from single 
transfected ones and compare the fluorescence of each, which would have the purpose of 
comparing the proliferation of cells which have only one or another gene knocked down, or 
have a knock down of both genes. 
 
 
 
 
 
 
GD 
TD 
      
Figure 21 Transfection of 293T cells with different combinations of SFLV
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The 6 shRNAs against CUX1, and 5 shRNAs against SH2B2 were retrieved from the    
Sigma-Aldrich library (www.sigmaaldrich.com) and Open Biosystems library 
(www.openbiosystems.com). Furthermore one scrambled sequence for each gene was cloned 
in the same vector as the appropriate gene. CUX1 shRNA pins were cloned into SFLV-BFP, 
and SH2B2 into the SFLV-RFP vector. The shRNAs were cloned into the vectors and after 
entering the cell, they were expressed through the SFFV promoter. According to the 
hypothesis that the cells with reduced expression of a target gene, mimicking 
haploinsufficiency, would have proliferative advantage, they would therefore outgrowth the 
cells that don’t have the knock down. The quantity of the cells expressing the pins was 
measured by the FACS machine. The fluorescence is measured over a period of time to assess 
if the knock down of one of the genes gives proliferative advantage to the cells. Proliferative 
advantages or disadvantages can be measured by comparing the initial and final fluorescence 
of the cells over a period of time.  
Over 6 weeks no significant differences were observed in growth dynamics of cells 
expressing pins targeting CUX1, neither in the 24-well plate (figure 22a), nor in the 96-well 
plate after spin infection (figure 22b). The visible small changes were comparable to those of 
the cells which either had only the empty vector, or the vector with a scrambled sequence 
(figure 22). In the figures showing the fluorescence of cells having a vector with a pin against 
SH2B2, an interesting pattern can be seen in the figure showing proliferation of cells in the 
96-well plate (figure 23b). In the 24-well plate no significant changes, apart from the drop of 
fluorescence after 33 days that rose again after 7 more days, were observed (figure 23a). The 
cells transduced in a 96-well format, however, had very instable percentages of fluorescence. 
In a period of about 5 to 22 days, the fluorescence of cells with all shRNAs, as well as the 
empty vector, and the control, raised and fell significantly (figure 23b). However, there was 
no remarkable change of the fluorescence intensity of any shRNA.  
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Figure 22 Proliferation of Baf3/EpoR cells transfected with shRNAs against CUX1 
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Figure 23 Proliferation of Baf3/EpoR cells transfected with shRNAs against SH2B2 
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 Another possibility to screen the different shRNAs and test if one leads to a p
advantage, was to stress the transduced cells
100µM hydroxyurea (HU), which is used for treatment of MPN patients, to the med
after 6 days, when the viability of
without HU, and look for prol
cells which have a shRNA which
in figures 24 and 25, one can see
cells that survived the treatment and
cells was to let them grow
concentration of 1U/mL, 
conferred proliferative advantage of 
Figure 24 Treatment of Baf3/EpoR cells transfected with shRNAs against 
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 in a variety of ways. One 
 cells strongly decreases, change the medium again to one 
iferative advantage. All cells were killed by 
 gives an advantage, would outgrowth the others. However, 
 that none of the pins conferred proliferative advantage to the 
 reached the initial viability. A second method of stressing 
 in medium with reduced concentration of Epo. 
0,01U/mL was used, but again in this experiment, no shRNA 
the cells (figure 26-27). 
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Figure 25 Treatment of Baf3/EpoR cells transfected with shRNAs against 
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SH2B2 with hydroxyurea
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Figure 26 Growth of Baf3/EpoR cells transfected with shRNAs against CUX1 in media with different concentrations of Epo 
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Figure 27 Growth of Baf3/EpoR cells transfected with shRNAs against SH2B2 in media with different concentrations of 
erythropoietin 
 
In order to confirm the knock down of CUX1 and SH2B2, RNA from cells was prepared, and 
by performing reverse transcription, cDNA was synthesized. The expression levels of the two 
genes, normalized to actin, and measured by real time PCR, are shown in figure 28. No 
significant change could be seen in the expression of CUX1, especially when comparing it to 
the expression of CUX1 in cells which had only the empty vector or the scrambled 
oligonucleotide as control. Only the knock down of CUX1was analyzed, because the 
transduction rates of SH2B2 were much lower than those of CUX1, and because of this, 
expression analysis could not be performed. For enrichment of transduced cells, the cells were 
grown in 700µg/mL hygromycin for 9 days. After day 5 no enrichment was observed (data 
not shown). The SFLV vector contains a resistance gene against hygromycin, and because of 
this, cells having the vector should be the only ones growing in this medium. After this time, 
only cells carrying some pins survived and were able to be enriched at >90%. Only the cells 
with the scrambled sequence, and with three different shRNAs against CUX1, survived 
(figure 29-31). However, also after enrichment of these cells, no decrease of CUX1 expression 
could be observed compared to the control (figure 29-31). 
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 Figure 28 CUX1 expression in Baf3/EpoR cells transduced
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Figure 29 CUX1 expression in Baf3/EpoR cells 
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Figure 30 CUX1 expression in Baf3/EpoR cells 
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4.3 TP53 
In order to analyze another gene, which could play an important role in MPN pathogenesis, 
and is associated with transformation to post-MPN AML, the 11 exons of TP53 were 
sequenced from 24 patients that experienced disease progression to sMF or post-MPN AML. 
For all patients there were at least two paired DNA samples available, one collected in the 
chronic phase of the disease and the second after disease evolution. Five of the patients (21%) 
had a TP53 mutation. 24 One patient had a homozygous mutation, two had independent 
mutations on both TP53 alleles, and two had a monoallelic mutation (one point mutation and 
one 19bp deletion) (table 12). For these patients the samples from the chronic phase were also 
analyzed. Two of them displayed the mutations also in chronic phase, but one carried the 
mutations in a smaller clone and the other had only one of the two mutations before disease 
progression.24 
 
Table 12 Sequencing results of TP53 in patients with disease progression (UPN unique patient number)
24 
 
 
 
  UPN 1 
UPN 2 
UPN 3 
UPN 4 
UPN 5 
53 
 
5 DISCUSSION 
The purpose of this study was to identify a new tumor suppressor or oncogene which would 
play a role in the pathogenesis of MPN. MPN are a very heterogeneous disease group,18 
because of the many different genes playing a role in the pathogenesis. Up to now it remains 
unknown whether a founder mutation driving the clonality exists. In an attempt to find this 
common mutation, which could lead to better diagnosis and treatment of MPN, three genes 
with possible involvement in the pathogenesis were studied.  
CUX1 and SH2B2 were found in the CDR of chromosome 7q using 6.0 arrays. CUX1 was 
often suggested before to play a role in myeloid malignancies,99 but only very recently,           
a mutation was found.105 SH2B2 belongs to one gene family with SH2B3, which was also 
recently reported to be a tumor suppressor in MPN.129-130 Our CDR found in chronic and 
transformed MPN patients, contained only one gene, CUX1. However, because of the 
relatedness of SH2B2 to SH2B3, it was also interesting to search for mutations in SH2B2. It 
might be, that a deletion of one of the two genes would lead to a weaker phenotype, and a 
deletion of both would result in a stronger phenotype. Only one mutation in SH2B2, but no 
somatic mutation in CUX1, was found in 32 patients with post-MPN AML.  
On chromosome 12q a duplication of the chromosomal region of 7q can be found. CUX2 and 
SH2B3 are located in this duplicated region, and both are suggested to play a role in the 
pathogenesis of MPN.129-130, 146 A duplication of a gene is a mechanism by which evolution 
multiplies genes that are important during evolution.167 This is also an argument in favor of 
the hypothesis that CUX1 and SH2B2 could be important for MPN pathogenesis. It also 
supports the theory, that MPN are complex diseases, and that the patients constitute a very 
heterogeneous group.18 We could see from the 6.0 array analyses that five out of six target 
genes of the CDRs, FOXP1, IKZF1, CUX1, ETV6, and RUNX1, are transcription factors. This 
could mean that transcription factor networks could have a big impact on MPN pathogenesis 
if disturbed.21 One possibility to study this, would be to compare the expression levels of 
different genes in cells, which have a knock down of one important gene for MPN, and search 
for the common ones with altered expression. It is possible that these genes, which are found 
down-regulated, constitute a network.  
 For further analysis of the function of CUX1 and SH2B2 in MPN, it was attempted to analyze 
the impact of shRNA pins against these genes on Baf3/EpoR cell kinetics. For that, a knock 
down of CUX1 and SH2B2 using shRNAs was conducted. A screen of the different pins 
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showed no significant change in the proliferative advantage of cells containing the different 
pins. This could be due to an insufficient knock down of the gene of interest, or could mean 
that these genes do not play a major role in the pathogenesis of MPN. To re-evaluate the 
hypothesis, more experiments can be envisioned. The irregular pattern of fluorescence of cells 
containing the vector with the RFP marker could be due to toxicity of the marker, which 
manifests after reaching a certain concentration, or because of an inefficient translation and 
folding of the marker protein. These results call for caution when using RFP as a cell tracer. 
One shRNA against SH2B2 had a transduction rate of 0% in all experiments, which could be 
either due to a toxicity of this pin, or due to too low concentrations of DNA used for 
production of the virus. The results of the real time PCR, showing that there is no knock down 
of CUX1, could be in figure 28 due to the different transduction efficiencies of the cells. 
Single copy integrations might not be enough to reach good knock down efficiencies, that is 
why an increase in MOI (multiplicity of infection) might be useful. To study the expression 
level of CUX1 and SH2B2, it would be necessary to get 100% enriched cells for all the 
shRNAs, and then check again the knock down efficiency. One of the possibilities to sort the 
cells according to their fluorescence would be to perform FACS sorting or improve the 
antibiotic selection. Nevertheless, for 3 shRNAs against CUX1 a ~100% enrichment of 
fluorescent cells with hygromycin was achieved. These were the only cells which survived 
after the hygromycin treatment. Measurement of CUX1 expression in these cells also resulted 
in no effect, but here the normalization to actin could play a role, because its expression was 
too high (figure 29-31). Whether the efficiency of the used pins against CUX1 was enough 
needs still to be verified. CUX1 has a very large transcript and multiple variants, which could 
hinder its knock down.  
Another interesting study would be to make double transduction of cells with shRNAs against 
CUX1 and SH2B2, and look if a cell, which has both genes knocked down, gets proliferative 
advantage. One could also include a third gene, for example SH2B3, or CUX2, and look, if 
there is some cumulative effect that confers stronger proliferative advantage. The shRNAs, 
which would be proven to confer a knock down of CUX1 and SH2B2, could be also later used 
for in vivo studies in bone marrow transplantation experiments in mice to assess the role of 
CUX1 and SH2B2 in the pathogenesis of MPN. As an alternative to knock down technologies, 
the careful analysis of mice with Cux1 and Sh2b2 deletions might be useful in determining 
any cooperative effect between the genes.  
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